Format

Send to

Choose Destination
J Am Coll Cardiol. 2014 Jan 21;63(2):110-22. doi: 10.1016/j.jacc.2013.08.724. Epub 2013 Sep 11.

Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction).

Author information

1
Cedars-Sinai Heart Institute, Los Angeles, California.
2
Division of Cardiology, Department of Medicine, Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, Illinois.
3
EMMES Corporation, Rockville, Maryland.
4
Division of Cardiology, Department of Medicine, The Johns Hopkins University, Baltimore, Maryland.
5
Division of Cardiology, Department of Medicine, The Johns Hopkins University, Baltimore, Maryland; Department of Biomedical Engineering, The Johns Hopkins University, Baltimore, Maryland.
6
Cedars-Sinai Heart Institute, Los Angeles, California. Electronic address: eduardo.marban@csmc.edu.

Abstract

OBJECTIVES:

This study sought to report full 1-year results, detailed magnetic resonance imaging analysis, and determinants of efficacy in the prospective, randomized, controlled CADUCEUS (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction) trial.

BACKGROUND:

Cardiosphere-derived cells (CDCs) exerted regenerative effects at 6 months in the CADUCEUS trial. Complete results at the final 1-year endpoint are unknown.

METHODS:

Autologous CDCs (12.5 to 25 × 10(6)) grown from endomyocardial biopsy specimens were infused via the intracoronary route in 17 patients with left ventricular dysfunction 1.5 to 3 months after myocardial infarction (MI) (plus 1 infused off-protocol 14 months post-MI). Eight patients were followed as routine-care control patients.

RESULTS:

In 13.4 months of follow-up, safety endpoints were equivalent between groups. At 1 year, magnetic resonance imaging revealed that CDC-treated patients had smaller scar size compared with control patients. Scar mass decreased and viable mass increased in CDC-treated patients but not in control patients. The single patient infused 14 months post-MI responded similarly. CDC therapy led to improved regional function of infarcted segments compared with control patients. Scar shrinkage correlated with an increase in viability and with improvement in regional function. Scar reduction correlated with baseline scar size but not with a history of temporally remote MI or time from MI to infusion. The changes in left ventricular ejection fraction in CDC-treated subjects were consistent with the natural relationship between scar size and ejection fraction post-MI.

CONCLUSIONS:

Intracoronary administration of autologous CDCs did not raise significant safety concerns. Preliminary indications of bioactivity include decreased scar size, increased viable myocardium, and improved regional function of infarcted myocardium at 1 year post-treatment. These results, which are consistent with therapeutic regeneration, merit further investigation in future trials. (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction [CADUCEUS]; NCT00893360).

KEYWORDS:

CDC; CK-MB; CT; DSMB; Data and Safety Monitoring Board; EDV; EF; ESV; Ecc; FWHM; ICD; LV; LVEF; MI; MRI; NYHA; New York Heart Association; SAE; TnI; Vo(2); cardiosphere-derived cell; cardiosphere-derived cells; computed tomography; creatine kinase-myocardial band; ejection fraction; end-diastolic volume; end-systolic volume; full width at half maximum; implantable cardioverter-defibrillator; left ventricular; left ventricular ejection fraction; magnetic resonance imaging; myocardial infarction; myocardial regeneration; oxygen consumption; serious adverse event(s); systolic circumferential strain; troponin I

PMID:
24036024
PMCID:
PMC3947063
DOI:
10.1016/j.jacc.2013.08.724
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center